Nothing approved today restores a failing kidney, and the drugs that slow it were not designed for the cell that is sick. Ours are. The target comes from the twin, the medicine is written as a sequence against it, and it is given to the patients whose own tissue shows that biology.
A platform that nominates targets is not a drug company, and a target that never becomes a medicine helps nobody. What makes it one is the chain below: each step is a real decision with a real failure mode, and we do not skip any of them.
Specific programmes, sequences and delivery chemistries are not disclosed publicly. Partners can review them under agreement.
A new target means a new sequence, not a new chemical series. Design time is measured in weeks, so a target can be acted on while it is still the right one.
Backbone chemistry, delivery and manufacturing carry from one programme to the next. The investment compounds rather than being written off.
Many genes that human genetics points to have no binding pocket. Silencing a transcript does not require one to exist.
Kidney trials have been long because the endpoint moves slowly. The models that pick the target also pick the patient and read the response, which is what makes a trial of reasonable size possible.
Recruit the patients whose disease is actually moving, not everyone with a diagnosis.
Treat the patients whose own tissue shows the biology the medicine addresses.
Blood and tissue readouts that move before function does, used as interim evidence.
Every outcome, positive or not, is evidence the next programme is designed with.